149 related articles for article (PubMed ID: 12649114)
1. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
[TBL] [Abstract][Full Text] [Related]
2. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
4. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
7. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.
Chatelut E; Pivot X; Otto J; Chevreau C; Thyss A; Renée N; Milano G; Canal P
Eur J Cancer; 2000 Jan; 36(2):264-9. PubMed ID: 10741287
[TBL] [Abstract][Full Text] [Related]
8. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
[TBL] [Abstract][Full Text] [Related]
9. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
[TBL] [Abstract][Full Text] [Related]
10. A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck.
Cattel L; Recalenda V; Airoldi M; Tagini V; Delprino L; Rocco F; Bumma C
Farmaco; 2001 Sep; 56(9):695-9. PubMed ID: 11680814
[TBL] [Abstract][Full Text] [Related]
11. Combined modality treatment using concurrent radiotherapy and pharmacologically-guided carboplatin for inoperable and incompletely resected non-small cell lung cancer.
Grossi M; Millward M; Fisher R; Porceddu S; Mac Manus M; Ryan G; Wirth A; Ball D
Lung Cancer; 2001 Jan; 31(1):73-82. PubMed ID: 11162869
[TBL] [Abstract][Full Text] [Related]
12. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy.
Rubie H; Doz F; Vassal G; Chastagner P; Gentet JC; Urien S; Bastian G; Drouard-Troalen L; Barberi-Heyob M; Catalin J; Chatelut E;
Eur J Cancer; 2003 Jul; 39(10):1433-8. PubMed ID: 12826047
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer.
Sato E; Yano I; Jiko M; Takahashi K; Motohashi H; Masuda S; Katsura T; Nishiyama H; Segawa T; Ito N; Kamoto T; Ogawa O; Inui K
Biol Pharm Bull; 2006 Jul; 29(7):1441-4. PubMed ID: 16819185
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.
Moeung S; Chevreau C; Broutin S; Guitton J; Lelièvre B; Ciccolini J; Massart C; Fléchon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Paci A; Marsili S; Malard L; Chatelut E; Thomas F
Clin Cancer Res; 2017 Dec; 23(23):7171-7179. PubMed ID: 28928162
[No Abstract] [Full Text] [Related]
15. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
Herrington JD; Tran HT; Riggs MW
Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule.
Ando Y; Minami H; Saka H; Ando M; Sugiura S; Sakai S; Shimokata K
Jpn J Cancer Res; 1997 May; 88(5):517-21. PubMed ID: 9247610
[TBL] [Abstract][Full Text] [Related]
17. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
18. Prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Chatelut E; Canal P; Brunner V; Chevreau C; Pujol A; Boneu A; Roché H; Houin G; Bugat R
J Natl Cancer Inst; 1995 Apr; 87(8):573-80. PubMed ID: 7752255
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
van Warmerdam LJ; Rodenhuis S; van der Wall E; Maes RA; Beijnen JH
Br J Cancer; 1996 Apr; 73(8):979-84. PubMed ID: 8611435
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
